Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 138.60 804,182 16:35:13
Bid Price Offer Price High Price Low Price Open Price
138.20 139.00 139.40 138.00 139.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 190.60 131.30 20.50 6.8 826
Last Trade Time Trade Type Trade Size Trade Price Currency
17:10:47 O 250,000 138.369 GBX

Vectura (VEC) Latest News (13)

More Vectura News
Vectura Investors    Vectura Takeover Rumours

Vectura (VEC) Discussions and Chat

Vectura Forums and Chat

Date Time Title Posts
11/6/202121:33Vectura - An emerging Pharmaceutical Co.11,663
04/4/200620:42A winner.87

Add a New Thread

Vectura (VEC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-11 16:11:14138.37250,000345,922.50O
2021-06-11 15:40:43138.6079,102109,635.45O
2021-06-11 15:35:13138.60220,522305,643.49UT
2021-06-11 15:30:00139.001,9292,681.31O
2021-06-11 15:29:59138.401,1011,523.78AT
View all Vectura trades in real-time

Vectura (VEC) Top Chat Posts

Vectura Daily Update: Vectura Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VEC. The last closing price for Vectura was 138.60p.
Vectura Group Plc has a 4 week average price of 114p and a 12 week average price of 109.80p.
The 1 year high share price is 163.80p while the 1 year low share price is currently 91.90p.
There are currently 596,154,987 shares in issue and the average daily traded volume is 14,442,585 shares. The market capitalisation of Vectura Group Plc is £826,270,811.98.
a1ord53: I think shareprice is higher, because existing shareholders/today’s buyers will get average price lower than 155p and it gives them additional short term profit and not because they look for higher bid - it’s my view and opinion. Example : for those who had bought at 122p or lower , today’s share price 162 p means average price under 155p will result in profit - so easy ) If no higher bid , current share price is great - gives 8 p additional premium !
rolo7: Vec share price will increase after consolidation by one 5th its a 4/5 share consolidation? vec will remain in fste 250 this time next month.
polaris: The Special Dividend is expected to become payable to shareholders on 11 June 2021. Shareholders will have the opportunity to invest the proposed Special Dividend to purchase additional ordinary shares in the Company through the Company's dividend reinvestment plan ("DRIP"). The Company will publish a circular ("Shareholder Circular") on 23 April 2021, setting out the details of the proposed Special Dividend and Share Consolidation and convening a general meeting (the "General Meeting") to be held at 11.00 a.m. BST on Thursday 27 May 2021 (or as soon thereafter as the 2021 annual general meeting of the Company to be held on the same day (the "2021 AGM") is concluded or adjourned). Will Downie, Chief Executive Officer of Vectura, said: "We are pleased to confirm today our intention to pay a special dividend to shareholders, following the conclusion of the US litigation process with GSK. We remain focused on the execution of our CDMO strategy and with a robust balance sheet, even following this material return to shareholders, we are in a strong position to invest for future growth." Further details regarding the Special Dividend and Share Consolidation Special Dividend The proposed Special Dividend of approximately GBP113 million in aggregate represents 19 pence per Existing Ordinary Share. The Board is proposing to pay the Special Dividend to Shareholders on the Register as at 6.00 p.m. on 28 May 2021. Subject to the passing of the relevant Resolutions at the General Meeting , the Special Dividend is expected to become payable to Shareholders on 11 June 2021. From RNS on 21st April hTTps://
gbcol: Thanks guys. I got a quick response from IR, rather vague and global so I expect that they have had a few people querying it. Basically 3 points. First, that the value of my holding will not reduce overall as a result of the divi/consolidation. Whoppee-do. That’s the theory anyway, we’ll see. Not a reason for doing it though, in any case. Second, without consolidation, divi would adversely affect the share price chart. Thirdly, that share consolidations usually increases the share price - which I would seriously question. Possibly there might be something in the increase in EPS that Polaris mentioned but I’m struggling for a reason to vote for it. Mine are held in SIPP & ISA so no tax issues for me but I’m not sure if I’d be able to take advantage of the DRIP (will have to check with them). So, if not and I believe share price should be above current levels - which I do - I’ll have to buy back my reduced holding on the open market. Personally I would have gone for a small divi and maybe some buybacks but guess were stuck with this now.
popper joe: As far as I can see, the company have put a ceiling on the share price now until this dividend and consolidation is completed. Anyone buying at the moment is going to end up with five sixths of the number of shares that they buy plus 6 x 19p = £1.14 for each share that they lose. So why would anyone buy shares at a price above £1.14 when they will effectively be forced to sell 16.6% of there holding at that price in a few weeks time? The only benefit that I can see is that the DRIP exercise may put some upward pressure on the share price.
polaris: The target from several years ago was met. Shame i missed the bulk of it due to bad position timing and losses elsewhere forcing me to close. Anyone who did ride it from 70 to 125 must be happy. Now, i am in for trading reasons. I know what my limits are set at. They are way below some of the forecasts here but i do think the share price is lower than it should be given the current prospects. That is down to lack of thrust from management. I am disappointed with apparent lack of progress on Ellipta. QVM149 will add to revenues this year and into the future. Disappointed with the VR315 approval/launch farce (though that lies squarely with Hikma). Disappointed with Symbicort generic in Europe. VR2081 seems to have also disappeared without trace - the US version of this. VEC and partners should be promoting these developments and timeline. They are not. That is why the share price is languishing. Those developments have a lot of latent value...given the right promotion. I believe that VEC trades at less than the sum of its parts. However, i do feel this management team have failed to light things up. If they really were a leading CDMO i'd expect the cash to go on acquisitions to bolster that position. They are bit-part players running a company that relies on legacy IP, albeit very lucrative legacy IP.
richman777114: polaris,one could almost imagine a lid is being kept on the VEC share price to make a circa 140p offer look attractive to weary shareholdersIMHO
a1ord53: FT: “Share price forecast The 6 analysts offering 12 month price targets for Vectura Group PLC have a median target of 132.00, with a high estimate of 149.00 and a low estimate of 126.00. The median estimate represents a 14.58% increase from the last price of 115.20 29.3% from 149.00 Med 14.6% from 132.00 Low 9.4% from 126.00 .” PS The lowest Price Target 10% higher than current price. Imo after GSK petition expiry and divi date announcement end of April, Advair approval share price will move above 130-35 p fast.
polaris: Don't split hairs on the GSK side. VEC must now wait until it is 100 % sure that GSK do not petition before paying proceeds to shareholders. That is only prudent. I assume that the period was extended due to Covid situation, as i thought the period had lapsed for SC petition. The money is now with VEC!! Litigation award As announced on 19 November 2020, the United States Court of Appeals for the Federal Circuit denied GlaxoSmithKline's (GSK's) motions for judgment as a matter of law, a new trial on infringement and for a new trial on damages in litigation concerning Vectura's US patent 8303991, which is infringed by GSK's US sales of three Ellipta(R) products. On 28 December 2020 the Court issued a mandate obligating GSK to pay Vectura the damages for patent infringement, associated interest and ongoing royalties. An amount of GBP121.1m relating to damages and associated interest thereon has been recognised as exceptional income in 2020. Payments relating to royalties earned in the fourth quarter 2020 have been assessed as meeting the IFRS 15 requirements for revenue recognition, as will any future similar payments. This revenue has been earned pursuant the decision of the United States District Court for the District of Delaware and was upheld by the US Court of Appeals, which, amongst other damages, awarded Vectura ongoing royalties of 3% on US sales of three infringing GSK Ellipta(R) products. Legal fees of GBP0.9m (2019: GBP3.0m) relate to the costs associated with these legal proceedings. And: GSK litigation - US As announced on 19 November 2020, the United States Court of Appeals for the Federal Circuit denied GlaxoSmithKline's (GSK) motions for judgement as a matter of law, a new trial on infringement and for a new trial on damages in litigation concerning Vectura's US patent 8303991, which covers three of GSK's Ellipta(R) products sold in the US. GSK did not subsequently petition the US Court of Appeals for a re-hearing and paid GBP121.1m to Vectura in January 2021. This amount reflects damages, associated interest and royalties accrued up to the period ending Q3 2020. Within the 2020 financial results, Royalty and other marketed revenues include a total of GBP6.5m royalties recognised for Q4 2020 in respect of this award and the cash settlement for these royalties was received in February 2021. Additional royalties are payable for Q1 and Q2 2021, and amounts will be received in the quarter following reported sales. Amounts received are subject to taxation in the UK. Vectura expects to pay tax at rate of approximately 10% on these proceeds. GSK may petition the US Supreme Court to review the decision. Such a petition would not impact the timing of GSK making payments on the award. The Board consider that the likelihood of the US Supreme Court overturning the previous decisions is remote, based on the average acceptance rate of cases petitioned to US Supreme Court and the merits of the case.
a1ord53: Hikma, dripping down. Execution very poor concerning Advair. Vec trading - after taking huge 5,03% position by Polygon - brokers who sold it , hedging their CFD‘s - aprox equivalent of 30 mil Vec shares - its why so so volitile. Otherwise , look at major shareholders - they control 85% of Vectura - so no really big institutions left to buy Vectura - so only one exit strategy is to find buyer/s for all Vectura/ takeover. Fresh money imo not exists for Vectura ! Or Vectura will be growth company and will be rerated !?
Vectura share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 15:19:26